(Reuters) – Cipla, India’s third-largest generic drugmaker by sales, reported a second-quarter profit above expectations on Tuesday, driven by higher sales of its respiratory and cancer drugs in its key North American and domestic markets.
The company reported a 15.2% rise in its consolidated net profit to 13.03 billion rupees ($155 million) for the quarter ended Sept. 30, beating analysts’ estimate of 12.34 billion rupees, as per data compiled by LSEG.
($1 = 84.0480 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Abinaya Vijayaraghavan)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.